Droz C - Search Results

1

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM. Taburet AM, et al. Among authors: droz c. Clin Pharmacol Ther. 2004 Apr;75(4):310-23. doi: 10.1016/j.clpt.2003.12.013. Clin Pharmacol Ther. 2004. PMID: 15060509 Clinical Trial.

2

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM; Puzzle 1 Study Group. Raguin G, et al. Among authors: droz c. Antivir Ther. 2004 Aug;9(4):615-25. Antivir Ther. 2004. PMID: 15456093 Clinical Trial.

3

R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: droz c. Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6. doi: 10.1128/AAC.47.11.3623-3626.2003. Antimicrob Agents Chemother. 2003. PMID: 14576131 Free PMC article. Clinical Trial.

4

Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART.

Bonnet F, Savès M, Morlat PH, Droz C, Chêne G, Peuchant E, Bernard N, Lacoste D, Salamon R, Beylot J. Bonnet F, et al. Among authors: droz c. J Clin Immunol. 2002 Mar;22(2):75-82. doi: 10.1023/a:1014475618504. J Clin Immunol. 2002. PMID: 11998896

5

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group. Masquelier B, et al. Among authors: droz c. J Infect Dis. 2002 Nov 15;186(10):1503-7. doi: 10.1086/344358. Epub 2002 Oct 23. J Infect Dis. 2002. PMID: 12404170

6

Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.

Bonnet F, Savès M, Droz C, Peuchant E, Chêne G, Beylot J, Morlat P. Bonnet F, et al. Among authors: droz c. J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):199-200. doi: 10.1097/00042560-200010010-00017. J Acquir Immune Defic Syndr. 2000. PMID: 11103052 No abstract available.

7

Increase of lipid plasma concentrations under protease inhibitor-containing regimens are not related to modifications of the tumour necrosis factor system.

Bonnet F, Savès M, Droz C, Peuchant E, Chêne G, Beylot J, Morlat P. Bonnet F, et al. Among authors: droz c. AIDS. 2001 May 4;15(7):940-1. doi: 10.1097/00002030-200105040-00018. AIDS. 2001. PMID: 11399970 No abstract available.

8

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation.

Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N. Blin P, et al. Among authors: droz c. Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455. doi: 10.1002/cpt.1318. Epub 2019 Feb 6. Clin Pharmacol Ther. 2019. PMID: 30499605

9

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.

Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Heeke A, Huerta C, Martin Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjaer M, Andersen M, De Bruin ML, Groenwold R, van den Ham HA, Souverein P, Klungel O, Gardarsdottir H. Ibáñez L, et al. Among authors: droz c. Br J Clin Pharmacol. 2019 Nov;85(11):2524-2539. doi: 10.1111/bcp.14071. Epub 2019 Sep 4. Br J Clin Pharmacol. 2019. PMID: 31318059 Free PMC article.

10

Effectiveness of antibiotics for acute sinusitis in real-life medical practice.

Blin P, Blazejewski S, Lignot S, Lassalle R, Bernard MA, Jayles D, Théophile H, Bénichou J, Demeaux JL, Ebbo D, Franck J, Moride Y, Peyramond D, Rouveix B, Sturkenboom M, Gehanno P, Droz C, Moore N. Blin P, et al. Among authors: droz c. Br J Clin Pharmacol. 2010 Sep;70(3):418-28. doi: 10.1111/j.1365-2125.2010.03710.x. Br J Clin Pharmacol. 2010. PMID: 20716243 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters